Archives of Clinical Infectious Diseases

Published by: Kowsar
Crossmark
Uncorrected Proof scheduled for 14 (3)

The Relationship Between Serum IL-17 Level and Viral Load in Chronic Hepatitis B

Maliheh Metanat 1 , * , Ebrahim Alijani 2 , Alireza Ansari-Moghaddam ORCID 3 , Fatemeh Bahrehmand 1 , Manijeh Khalili 4 , Narges Arbabi 1 , Soheila Khosravi 5 , Esmaeil Sanei Moghadam 5 and Roya Alavi-Naini 1
Authors Information
1 Infectious Diseases and Tropical Medicine Research Center, Resistant Tuberculosis Institute, Zahedan University of Medical Sciences, Zahedan, Iran
2 Clinical Immunology Research Center, Zahedan University of Medical Sciences, Zahedan, Iran
3 Health Promotion Research Center, Zahedan University of Medical Sciences, Zahedan, Iran
4 Children and Adolescents Health Research Center, Resistant Tuberculosis Institute, Zahedan University of Medical Sciences, Zahedan, Iran
5 Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Zahedan, Iran
Article information
  • Archives of Clinical Infectious Diseases: In Press (In Press); e68172
  • Published Online: June 11, 2019
  • Article Type: Research Article
  • Received: March 2, 2018
  • Revised: February 27, 2019
  • Accepted: March 10, 2019
  • DOI: 10.5812/archcid.68172

To Cite: Metanat M, Alijani E, Ansari-Moghaddam A , Bahrehmand F , Khalili M, et al. The Relationship Between Serum IL-17 Level and Viral Load in Chronic Hepatitis B, Arch Clin Infect Dis. Online ahead of Print ; In Press(In Press):e68172. doi: 10.5812/archcid.68172.

Abstract
Copyright © 2019, Archives of Clinical Infectious Diseases. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Gerlich WH, Bremer C, Saniewski M, Schuttler CG, Wend UC, Willems WR, et al. Occult hepatitis B virus infection: Detection and significance. Dig Dis. 2010;28(1):116-25. doi: 10.1159/000282074. [PubMed: 20460899].
  • 2. Pungpapong S, Kim WR, Poterucha JJ. Natural history of hepatitis B virus infection: An update for clinicians. Mayo Clin Proc. 2007;82(8):967-75. doi: 10.4065/82.8.967. [PubMed: 17673066].
  • 3. Salehi-Vaziri M, Sadeghi F, Almasi Hashiani A, Gholami Fesharaki M, Alavian SM. Hepatitis B virus infection in the general population of Iran: An updated systematic review and meta-analysis. Hepatitis Monthly. 2016;16(4). doi: 10.5812/hepatmon.35577.
  • 4. Valsamakis A. Molecular testing in the diagnosis and management of chronic hepatitis B. Clin Microbiol Rev. 2007;20(3):426-39. table of contents. doi: 10.1128/CMR.00009-07. [PubMed: 17630333]. [PubMed Central: PMC1932755].
  • 5. Lok AS, Conjeevaram HS. Hepatitis B. In: Schiff ER, Sorrell MF, Maddrey WC, editors. Schiff's diseases of the liver. 1. 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2003.
  • 6. Mohamed AA, Nada OH, El Desouky MA. Implication of protein kinase R gene quantification in hepatitis C virus genotype 4 induced hepatocarcinogenesis. Diagn Pathol. 2012;7:103. doi: 10.1186/1746-1596-7-103. [PubMed: 22894766]. [PubMed Central: PMC3487824].
  • 7. Moudi B, Heidari Z, Mahmoudzadeh-Sagheb H, Hashemi M, Metanat M, Khosravi S, et al. Association between IL-10 gene promoter polymorphisms (-592 A/C, -819 T/C, -1082 A/G) and susceptibility to HBV infection in an Iranian population. Hepat Mon. 2016;16(2). e32427. doi: 10.5812/hepatmon.32427. [PubMed: 27148384]. [PubMed Central: PMC4852092].
  • 8. Iannacone M, Sitia G, Isogawa M, Marchese P, Castro MG, Lowenstein PR, et al. Platelets mediate cytotoxic T lymphocyte-induced liver damage. Nat Med. 2005;11(11):1167-9. doi: 10.1038/nm1317. [PubMed: 16258538]. [PubMed Central: PMC2908083].
  • 9. Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003;52(1):65-70. doi: 10.1136/gut.52.1.65. [PubMed: 12477762]. [PubMed Central: PMC1773503].
  • 10. Matsuoka S, Nirei K, Tamura A, Nakamura H, Matsumura H, Oshiro S, et al. Influence of occult hepatitis B virus coinfection on the incidence of fibrosis and hepatocellular carcinoma in chronic hepatitis C. Intervirology. 2008;51(5):352-61. doi: 10.1159/000187720. [PubMed: 19127078].
  • 11. Romagnani S. Human Th17 cells. Arthritis Res Ther. 2008;10(2):206. doi: 10.1186/ar2392. [PubMed: 18466633]. [PubMed Central: PMC2453756].
  • 12. Gaffen SL. An overview of IL-17 function and signaling. Cytokine. 2008;43(3):402-7. doi: 10.1016/j.cyto.2008.07.017. [PubMed: 18701318]. [PubMed Central: PMC2582446].
  • 13. Zhu X, Mulcahy LA, Mohammed RA, Lee AH, Franks HA, Kilpatrick L, et al. IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res. 2008;10(6):R95. doi: 10.1186/bcr2195. [PubMed: 19014637]. [PubMed Central: PMC2656888].
  • 14. Kozlowski L, Zakrzewska I, Tokajuk P, Wojtukiewicz MZ. Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Rocz Akad Med Bialymst. 2003;48:82-4. [PubMed: 14737948].
  • 15. Zamani B, Moraveji SA, Ehteram H, Shikrani M. [Correlation between the serum level of IL-17 and rheumatoid arthritis]. J Kashan Univ Med Sci. 2015;19(1):47-53. Persian.
  • 16. Garrett-Sinha LA, John S, Gaffen SL. IL-17 and the Th17 lineage in systemic lupus erythematosus. Curr Opin Rheumatol. 2008;20(5):519-25. doi: 10.1097/BOR.0b013e328304b6b5. [PubMed: 18698171].
  • 17. Maloy KJ. The Interleukin-23 / Interleukin-17 axis in intestinal inflammation. J Intern Med. 2008;263(6):584-90. doi: 10.1111/j.1365-2796.2008.01950.x. [PubMed: 18479257].
  • 18. Song C, Luo L, Lei Z, Li B, Liang Z, Liu G, et al. IL-17-producing alveolar macrophages mediate allergic lung inflammation related to asthma. J Immunol. 2008;181(9):6117-24. doi: 10.4049/jimmunol.181.9.6117. [PubMed: 18941201].
  • 19. Rutitzky LI, Lopes da Rosa JR, Stadecker MJ. Severe CD4 T cell-mediated immunopathology in murine schistosomiasis is dependent on IL-12p40 and correlates with high levels of IL-17. J Immunol. 2005;175(6):3920-6. doi: 10.4049/jimmunol.175.6.3920. [PubMed: 16148138].
  • 20. Zelante T, De Luca A, Bonifazi P, Montagnoli C, Bozza S, Moretti S, et al. IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. Eur J Immunol. 2007;37(10):2695-706. doi: 10.1002/eji.200737409. [PubMed: 17899546].
  • 21. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006;24(2):179-89. doi: 10.1016/j.immuni.2006.01.001. [PubMed: 16473830].
  • 22. Wang L, Chen S, Xu K. IL-17 expression is correlated with hepatitis Brelated liver diseases and fibrosis. Int J Mol Med. 2011;27(3):385-92. doi: 10.3892/ijmm.2011.594. [PubMed: 21225222].
  • 23. Zhang JY, Zhang Z, Lin F, Zou ZS, Xu RN, Jin L, et al. Interleukin-17-producing CD4(+) T cells increase with severity of liver damage in patients with chronic hepatitis B. Hepatology. 2010;51(1):81-91. doi: 10.1002/hep.23273. [PubMed: 19842207].
  • 24. Shi M, Wei J, Dong J, Meng W, Ma J, Wang T, et al. Function of interleukin-17 and -35 in the blood of patients with hepatitis B-related liver cirrhosis. Mol Med Rep. 2015;11(1):121-6. doi: 10.3892/mmr.2014.2681. [PubMed: 25323532]. [PubMed Central: PMC4237084].
  • 25. Xu Y, Du WJ, Qin LY, Xing ZZ, Qin XH, Chen SJ. [Expression of interleukin-17 in hepatitis B related liver fibrosis]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2009;25(2):133-5. Chinese. [PubMed: 19174010].
  • 26. Du WJ, Zhen JH, Zeng ZQ, Zheng ZM, Xu Y, Qin LY, et al. Expression of interleukin-17 associated with disease progression and liver fibrosis with hepatitis B virus infection: IL-17 in HBV infection. Diagn Pathol. 2013;8:40. doi: 10.1186/1746-1596-8-40. [PubMed: 23448394]. [PubMed Central: PMC3598543].
  • 27. Feng H, Yin J, Han YP, Zhou XY, Chen S, Yang L, et al. Regulatory T cells and IL-17(+) T helper cells enhanced in patients with chronic hepatitis B virus infection. Int J Clin Exp Med. 2015;8(6):8674-85. [PubMed: 26309519]. [PubMed Central: PMC4538083].
  • 28. El-Gazzar AA, El-Basuoni MA, Soliman MA, Zaghla HE, Allam MM. Interleukin-17-producing CD4+T cells in patients with chronic hepatitis B. Menoufia Medical Journal. 2014;27(4):775. doi: 10.4103/1110-2098.149753.
  • 29. Yu X, Guo R, Ming D, Deng Y, Su M, Lin C, et al. The transforming growth factor beta1/Interleukin-31 pathway is upregulated in patients with hepatitis B virus-related acute-on-chronic liver failure and is associated with disease severity and survival. Clin Vaccine Immunol. 2015;22(5):484-92. doi: 10.1128/CVI.00649-14. [PubMed: 25716231]. [PubMed Central: PMC4412936].
  • 30. Wu W, Li J, Chen F, Zhu H, Peng G, Chen Z. Circulating Th17 cells frequency is associated with the disease progression in HBV infected patients. J Gastroenterol Hepatol. 2010;25(4):750-7. doi: 10.1111/j.1440-1746.2009.06154.x. [PubMed: 20492330].
  • 31. Meng P, Zhao S, Niu X, Fu N, Su S, Wang R, et al. Involvement of the Interleukin-23/Interleukin-17 axis in chronic hepatitis C virus infection and its treatment responses. Int J Mol Sci. 2016;17(7). doi: 10.3390/ijms17071070. [PubMed: 27428948]. [PubMed Central: PMC4964446].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments